Harbour BioMed

Harbour BioMed, a biopharmaceutical company focused on the research and development, commercialization, and global operations of innovative drugs, creates biologics with significant clinical value for oncology and immunological diseases. Harbour BioMed leverages its robust core technology platform portfolio to rapidly build a highly innovative and differentiated antibody drug pipeline. The company’s proprietary Harbour Mice® platform generates fully human antibodies (H2L2) with two heavy chains and two light chains, as well as fully human heavy-chain antibodies (HCAb). Additionally, based on HCAb, we have developed the HBICETM immune cell engager platform to create next-generation bispecific antibodies, achieving anti-tumor efficacy that traditional combination therapies cannot attain. These antibody development platforms, together with the single-cell cloning platform, form Harbour BioMed’s unique and efficient R&D engine for next-generation innovative therapeutic antibodies. "Innovative Medicines for Health" is the vision of Harbour BioMed. To realize this vision, we engage in internationally innovative collaborations with top-tier academic institutions and biopharmaceutical companies worldwide. Through independent innovation and diversified partnerships, we comprehensively advance the development of next-generation innovative therapies. Meanwhile, the company also licenses its technologies globally to biopharmaceutical enterprises and academic institutions, enhancing industry innovation capabilities and accelerating the delivery of more innovative therapies to patients.